Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

A Study to Evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) in the Reduction of Clinical Asthma Exacerbations in Patients (12-75 Years of Age) With Eosinophilic Asthma

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Teva Pharmaceutical Industries ( Teva Branded Pharmaceutical Products, R&D Inc. )
ClinicalTrials.gov Identifier:
NCT01287039
First received: January 28, 2011
Last updated: May 26, 2016
Last verified: May 2016
  Purpose
This is a Phase 3, multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy, safety, and immunogenicity of treatment with reslizumab in patients with eosinophilic asthma.

Condition Intervention Phase
Eosinophilic Asthma
Drug: Reslizumab
Drug: Placebo
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A 12-Month, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) in the Reduction of Clinical Asthma Exacerbations in Patients (12-75 Years of Age) With Eosinophilic Asthma

Resource links provided by NLM:


Further study details as provided by Teva Pharmaceutical Industries:

Primary Outcome Measures:
  • Frequency of Clinical Asthma Exacerbations (CAEs) During 12 Months of Treatment [ Time Frame: Day 1 to Week 52 ] [ Designated as safety issue: No ]

    An exacerbation event was considered a CAE if the patient met either or both of the criteria listed below and this was corroborated with at least 1 other measurement to indicate the worsening of clinical signs and symptoms of asthma:

    • use of systemic, or an increase in the use of inhaled, corticosteroid treatment for 3 or more days; or an increased 2 or more fold for at least 3 or more days for patient's already on corticosteroids.
    • asthma-related emergency treatment, such as an unscheduled visit to the physician's office or emergency room for nebulizer treatment or other urgent treatment to prevent worsening of asthma symptoms, or an asthma-related hospitalization CAEs were adjudicated by committee to assure consistency.

    Adjusted CAE rate and confidence intervals were based on Negative Binomial regression model adjusted for stratification factors.

    Results are offered as adjusted means.


  • Frequency of Each of the Two Criteria for Clinical Asthma Exacerbations (CAEs) [ Time Frame: Day 1 to Week 52 ] [ Designated as safety issue: No ]

    An exacerbation event was considered a CAE if the patient met either or both of the criteria listed below and this was corroborated with at least 1 other measurement to indicate the worsening of clinical signs and symptoms of asthma:

    • use of systemic, or an increase in the use of inhaled, corticosteroid treatment for 3 or more days; or an increased 2 or more fold for at least 3 or more days for patient's already on corticosteroids.
    • asthma-related emergency treatment, such as an unscheduled visit to the physician's office or emergency room for nebulizer treatment or other urgent treatment to prevent worsening of asthma symptoms, or an asthma-related hospitalization.

    CAEs were adjudicated by committee to assure consistency. Adjusted CAE rate and confidence intervals for the two criteria were based on Negative Binomial regression model adjusted for stratification factors.

    Results are offered as adjusted means.



Secondary Outcome Measures:
  • Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1) Over 16 Weeks Using Mixed Model for Repeated Measures [ Time Frame: Day 1 (baseline, pre-dose), Weeks 4, 8, 12 and 16 ] [ Designated as safety issue: No ]

    FEV1 is a standard measurement of air movement in the lungs of patients with asthma obtained from pulmonary function tests. It is the volume of air expired in the first second of a forced expiration using a spirometer. Positive change from baseline scores indicate improvement in asthma control.

    The during treatment (Weeks 4, 8, 12 and 16) average FEV1 was estimated using a mixed-effect model for repeated measures (MMRM) with fixed effects (treatment, stratification factors, sex, visit, interaction of treatment and visit), covariates (height, baseline value), and patient as the random effect for the repeated measurements.


  • Change From Baseline in Asthma Quality of Life Questionnaire (AQLQ) to Week 16 [ Time Frame: Day 1 (baseline, pre-dose), Week 16 ] [ Designated as safety issue: No ]

    The AQLQ is a 32-item instrument administered as a self-assessment (Juniper et al 1992). The questionnaire is divided into 4 domains: activity limitation, symptoms, emotional function, and environmental stimuli. Patients were asked to recall their experiences during the last 2 weeks and to respond to each question on a 7-point scale (1=severe impairment, 7=no impairment). The overall AQLQ score is the mean of all 32 responses. Five of the activity questions were "patient-specific," which means that each patient identified and scored 5 activities in which the patient was limited by asthma; these 5 activities were identified at the first visit and retained for all subsequent follow-up visits.

    Positive change from baseline scores indicate improvement in quality of life.


  • Change From Baseline in Asthma Control Questionnaire (ACQ) Over 16 Weeks Using Mixed Model for Repeated Measures [ Time Frame: Day 1 (baseline, pre-dose), Weeks 4, 8, 12, 16 ] [ Designated as safety issue: No ]

    The ACQ is a 7-item instrument that measures asthma control (Juniper et al 1999). Six questions are self-assessments; the seventh item, completed by a member of the study staff, is the result of the patient's FEV1 measurement. Each item has 7 possible answers on a scale of 0 to 6, and the total score is the mean of all responses (the total scale is therefore 0-6). A higher score is an indication of poorer asthma control. The during treatment (Weeks 4, 8, 12 and 16) average ACQ was estimated using a mixed-effect model for repeated measures (MMRM) with fixed effects (treatment, stratification factors, sex, visit, interaction of treatment and visit), covariates (height, baseline value), and patient as the random effect for the repeated measurements.

    Negative change from baseline scores indicate improvement in asthma control.


  • Kaplan-Meier Estimates for Time to First Clinical Asthma Exacerbation (CAE) [ Time Frame: Day 1 to Day 478 (longest treatment time plus 2 weeks) ] [ Designated as safety issue: No ]

    An exacerbation event was considered a CAE if the patient met either or both of the criteria listed below and this was corroborated with at least 1 other measurement to indicate the worsening of clinical signs and symptoms of asthma:

    • use of systemic, or an increase in the use of inhaled, corticosteroid treatment for 3 or more days; or an increased 2 or more fold for at least 3 or more days for patient's already on corticosteroids.
    • asthma-related emergency treatment, such as an unscheduled visit to the physician's office or emergency room for nebulizer treatment or other urgent treatment to prevent worsening of asthma symptoms, or an asthma-related hospitalization.

    CAEs were adjudicated by committee to assure consistency. The distributions were compared by a log rank test stratified by baseline usage of oral corticosteroid (yes or no) and geographical region (US or other).


  • Change From Baseline in Asthma Symptom Utility Index (ASUI) Over 16 Weeks Using Mixed Model for Repeated Measures [ Time Frame: Day 1 (baseline, pre-dose), Weeks 4, 8, 12, 16 ] [ Designated as safety issue: No ]

    The ASUI is an 11-item instrument designed to assess the frequency and severity of asthma symptoms and side effects, weighted by patient preferences (Revicki et al 1998). ASUI is a utility score that ranges from 0 to 1, with higher values indicating better asthma control; info obtained from questionnaire about asthma symptoms.

    The during treatment (Weeks 4, 8, 12 and 16) average ASUI was estimated using a mixed-effect model for repeated measures (MMRM) with fixed effects (treatment, stratification factors, sex, visit, interaction of treatment and visit), covariates (height, baseline value), and patient as the random effect for the repeated measurements.

    Positive change from baseline values indicate improvement in asthma symptoms. Information was obtained from questionnaire about asthma symptoms.


  • Change From Baseline in Short-Acting Beta-Agonist (SABA) Use Over 16 Weeks Using Mixed Model for Repeated Measures [ Time Frame: Day 1 (baseline, pre-dose), Weeks 4, 8, 12, 16 ] [ Designated as safety issue: No ]

    SABA are used for quick relief of asthma symptoms. To measure SABA use, at each clinical visit patients were asked to recall their usage of SABA therapy within the last 3 days of the scheduled visit. If usage was confirmed, the number of puffs used was recorded. For the purpose of summaries, an average daily usage was evaluated by dividing the total number of puffs recorded over 3 days by 3.

    The during treatment (Weeks 4, 8, 12 and 16) SABA use was estimated using a mixed-effect model for repeated measures (MMRM) with fixed effects (treatment, stratification factors, sex, visit, interaction of treatment and visit), covariates (height, baseline value), and patient as the random effect for the repeated measurements.

    Negative change from baseline scores indicate improvement in asthma control.


  • Change From Baseline in Blood Eosinophil Count Over 16 Weeks and 52 Weeks Using Mixed Model for Repeated Measures [ Time Frame: Day 1 (baseline, pre-dose), Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52 or early withdrawal ] [ Designated as safety issue: No ]

    Blood eosinophil counts were measured using a standard complete blood count (CBC) with differential blood test at each scheduled visit, and from all patients experiencing a serious adverse event, an adverse event leading to withdrawal, or an exacerbation of asthma symptoms.

    The during treatment average eosinophil counts were estimated using a mixed-effect model for repeated measures (MMRM) with fixed effects (treatment, stratification factors, sex, visit, interaction of treatment and visit), covariates (height, baseline value), and patient as the random effect for the repeated measurements.

    Negative change from baseline values correlate to reduced asthma severity.


  • Participants With Treatment-Emergent Adverse Events [ Time Frame: Day 1 (post-dose) to Week 65. The last postbaseline value for approximately 20 patients in each ] [ Designated as safety issue: Yes ]
    An adverse event was defined in the protocol as any untoward medical occurrence that develops or worsens in severity during the conduct of a clinical study and does not necessarily have a causal relationship to the study drug. Severity was rated by the investigator on a scale of mild, moderate and severe, with severe= an inability to carry out usual activities. Relation of AE to treatment was determined by the investigator. Serious AEs include death, a life-threatening adverse event, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability or incapacity, a congenital anomaly or birth defect, OR an important medical event that jeopardized the patient and required medical intervention to prevent the previously listed serious outcomes.

  • Participants With Treatment-Emergent Potentially Clinically Significant (PCS) Abnormal Lab Values [ Time Frame: Week 4 to Week 65. The last postbaseline value for approximately 20 patients in each ] [ Designated as safety issue: Yes ]

    Data represents participants with potentially clinically significant (PCS) abnormal serum chemistry, hematology, and urinalysis values.

    Significance criteria:

    • Blood urea nitrogen: >=10.71 mmol/L
    • Uric acid: M>=625, F>=506 μmol/L
    • Aspartate aminotransferase: >=3*upper limit of normal (ULN). Normal range is 10-43 U/L
    • Alanine aminotransferase: >=3*ULN. Normal range is 10-40 U/L
    • GGT = gamma-glutamyl transpeptidase: >= 3*ULN. Normal range is 5-49 U/L.
    • Bilirubin: >=34.2 μmol/L
    • White blood cells: <=3.0 or >20 10^9/L
    • Hemoglobin: M<=115, F<=95 g/dL
    • Hematocrit: M<0.37, F<0.32 L/L
    • Neutrophils: <=1.0 10^9/L
    • Eosinophils: >10.0 %
    • Platelets: <75 or >=700 10^9/L
    • Urinalysis: blood, glucose, ketones and total protein: >=2 unit increase from baseline

  • Participants With Treatment-Emergent Potentially Clinically Significant (PCS) Vital Signs Values [ Time Frame: Week 4 to Week 65. The last postbaseline value for approximately 20 patients in each ] [ Designated as safety issue: Yes ]

    Data represents participants with potentially clinically significant (PCS) vital sign values.

    Significance criteria

    • Sitting pulse - high 12-17 yr: >100 and increase of >= 30 beats/minute (bpm)
    • Sitting pulse - low >=18 yr: <50 and decrease of >=30 bpm
    • Sitting pulse - high >=18 yr: >100 and increase of >=30 bpm
    • Sitting systolic blood pressure - low >=18 yr: <90 and decrease of >=30 mmHg
    • Sitting systolic blood pressure - high >=18 yr: >160 and increase of >=30 mmHg
    • Sitting diastolic blood pressure - low 12-17 yr: <55 and decrease of >=12 mmHg
    • Sitting diastolic blood pressure - low >=18 yr: <50 and decrease of >=12 mmHg
    • Sitting diastolic blood pressure - high >=18 yr: >100 and increase of >=12 mmHg
    • Respiratory rate >=18 yr: >24 and increase of >=10 breaths/minute
    • Body temperature - low 12-17 yr: <96.5° Fahrenheit or <35.8° Celsius
    • Body temp - low >=18 yr: <96.5° F or <35.8° C
    • Body temp - high >=18 yr: >100.5° Fahrenheit

  • Participants With a Positive Anti-Reslizumab Antibody Status During Study [ Time Frame: Weeks 16, 32, 48 and 52 ] [ Designated as safety issue: Yes ]
    The immunogenicity of reslizumab was assessed by measuring for the presence of anti-reslizumab antibodies at baseline, weeks 16, 32, 48, and 52 or early withdrawal. Blood samples for anti-reslizumab antibodies assessment were also obtained from all patients (inside or outside of the US) experiencing a serious adverse event, an adverse event leading to withdrawal, or an exacerbation of asthma symptoms.


Enrollment: 489
Study Start Date: April 2011
Study Completion Date: March 2014
Primary Completion Date: December 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Placebo Comparator: Placebo
Placebo administered intravenously once every 4 weeks ( +-7 days) for a total of 13 doses.
Drug: Placebo
Matching placebo (20 mM sodium acetate, 7% sucrose), administered intravenously (iv) once every 4 weeks over 52 weeks, for a total of 13 doses administered. Each patient received a specific volume of placebo to match the volume of reslizumab on the basis of the patient's body weight.
Experimental: Reslizumab 3.0 mg/kg
Reslizumab 3.0 mg/kg administered intravenously once every 4 weeks ( +-7 days) for a total of 13 doses.
Drug: Reslizumab
Patients were administered intravenously over 15 to 30 minutes reslizumab at a dosage of 3.0 mg/kg at baseline and once every 4 weeks relative to baseline over 48 weeks for a total of 13 doses.
Other Names:
  • Cinquil
  • humanized monoclonal antibody
  • CEP-38072

Detailed Description:

Demonstrate the efficacy of reslizumab, at a dose of 3 mg/kg administered iv every 4 weeks over 12 months, as assessed by the reduction in frequency of clinical asthma exacerbations (CAEs) during 12 months.

An exacerbation event will be considered a CAE if the patient meets either or both of the criteria listed below and this is corroborated with at least 1 other measurement to indicate the worsening of clinical signs and symptoms of asthma:

  • use of systemic, or an increase in the use of inhaled, corticosteroid treatment for 3 or more days
  • asthma-related emergency treatment The above criteria must be corroborated with at least 1 other measurement to indicate worsening in the clinical signs and symptoms of asthma.
  Eligibility

Ages Eligible for Study:   12 Years to 75 Years   (Child, Adult, Senior)
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • The patient is male or female, 12 through 75 years of age, with a previous diagnosis of asthma.
  • The patient has had at least 1 asthma exacerbation requiring oral, intramuscular (im), or intravenous (iv) corticosteroid use for at least 3 days over the past 12 months before screening.
  • The patient has a current blood eosinophil level of at least 400/μl.
  • The patient has airway reversibility of at least 12% to beta-agonist administration.
  • The patient has an ACQ score of at least 1.5 at the screening and baseline (before the 1st dose of study drug) visits.
  • The patient is taking inhaled fluticasone at a dosage of at least 440 μg, or equivalent, daily. Chronic oral corticosteroid use (no more than 10 mg/day prednisone or equivalent) is allowed. If a patient is on a stable dose, eg, 2 weeks or more of oral corticosteroid treatment at the time of study enrollment, the patient must remain on this dose throughout the study. The patient's baseline asthma therapy regimen (including but not limited to inhaled corticosteroids, oral corticosteroids up to a maximum of 10 mg of prednisone daily or equivalent, leukotriene antagonists, 5-lipooxygenase inhibitors, or cromolyn) must be stable for 30 days prior to screening and baseline, and must continue without dosage changes throughout study.
  • All female patients must be surgically sterile, 2 years postmenopausal, or must have a negative pregnancy test ß-human chorionic gonadotropin [ß-HCG]) at screening (serum) and baseline (urine).
  • Female patients of childbearing potential (not surgically sterile or 2 years postmenopausal), must use a medically accepted method of contraception and must agree to continue use of this method for the duration of the study and for 30 days after participation in the study.
  • Written informed consent is obtained. Patients 12 through 17 years old must provide assent.
  • The patient is in reasonable health (except for diagnosis of asthma) as judged by the investigator, and as determined by a medical history, medical examination, ECG evaluation (at screening), serum chemistry, hematology, and urinalysis.

    • Other criteria apply; please contact the investigator for more information.

Exclusion Criteria:

  • The patient has a clinically meaningful co-morbidity that would interfere with the study schedule or procedures, or compromise the patient's safety.
  • The patient has known hypereosinophilic syndrome.
  • The patient has another confounding underlying lung disorder (eg, chronic obstructive pulmonary disease, pulmonary fibrosis, or lung cancer). Patients with pulmonary conditions with symptoms of asthma and blood eosinophilia (eg, Churg-Strauss syndrome, allergic bronchopulmonary aspergillosis) will also be excluded.
  • The patient is a current smoker (ie, has smoked within the last 6 months prior to screening).
  • The patient is using systemic immunosuppressive or immunomodulating or other biologic agents (including, but not limited to, anti-IgE mAb, methotrexate, cyclosporin, interferon-α, or anti-tumor necrosis factor [anti TNF] mAb) within 6 months prior to screening.
  • The patient has previously received an anti-hIL-5 monoclonal antibody (eg, reslizumab, mepolizumab, or benralizumab).
  • The patient has any aggravating medical factors that are inadequately controlled (eg, rhinitis, gastroesophageal reflux disease, and uncontrolled diabetes).
  • The patient has participated in any investigative drug or device study within 30 days prior to screening.
  • The patient has participated in any investigative biologics study within 6 months prior to screening.
  • Female patients who are pregnant, nursing, or, if of childbearing potential, and not using a medically accepted, effective method of birth control (eg, barrier method with spermicide, abstinence, IUD, or steroidal contraceptive [oral, transdermal, implanted, and injected]) are excluded from this study. NOTE: Partner sterility alone is not considered an acceptable form of birth control.

    • Other criteria apply; please contact the investigator for more information.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01287039

  Hide Study Locations
Locations
United States, Arizona
Teva Investigational Site 58
Scottsdale, Arizona, United States
United States, California
Teva Investigational Site 61
Los Angeles, California, United States
Teva Investigational Site 37
Orange, California, United States
Teva Investigational Site 56
San Diego, California, United States
United States, Colorado
Teva Investigational Site 34
Colorado Springs, Colorado, United States
United States, Florida
Teva Investigational Site 52
Debary, Florida, United States
Teva Investigational Site 55
Miami, Florida, United States
Teva Investigational Site 18
Valrico, Florida, United States
United States, Kentucky
Teva Investigational Site 49
Lexington, Kentucky, United States
Teva Investigational Site 65
Louisville, Kentucky, United States
United States, Massachusetts
Teva Investigational Site 51
Boston, Massachusetts, United States
United States, Missouri
Teva Investigational Site 74
St. Louis, Missouri, United States
United States, Montana
Teva Investigational Site 35
Missoula, Montana, United States
United States, Nebraska
Teva Investigational Site 64
Boys Town, Nebraska, United States
United States, New York
Teva Investigational Site 60
Bronx, New York, United States
Teva Investigational Site 68
Rochester, New York, United States
United States, North Carolina
Teva Investigational Site 30
Winston-Salem, North Carolina, United States
United States, Ohio
Teva Investigational Site 31
Cincinnati, Ohio, United States
Teva Investigational Site 62
Columbus, Ohio, United States
United States, Oklahoma
Teva Investigational Site 50
Oklahoma City, Oklahoma, United States
United States, Pennsylvania
Teva Investigational Site 66
Altoona, Pennsylvania, United States
United States, Tennessee
Teva Investigational Site 32
Nashville, Tennessee, United States
United States, Texas
Teva Investigational Site 63
Boerne, Texas, United States
Teva Investigational Site 72
Houston, Texas, United States
United States, Virginia
Teva Investigational Site 38
Richmond, Virginia, United States
United States, Wisconsin
Teva Investigational Site 33
Madison, Wisconsin, United States
Australia, Western Australia
Teva Investigational Site 643
Nedlands, Western Australia, Australia
Australia
Teva Investigational Site 641
Clayton, Australia
Teva Investigational Site 644
Daw Park, Australia
Teva Investigational Site 642
Frankston, Australia
Teva Investigational Site 645
Liverpool, Australia
Belgium
Teva Investigational Site 261
Bruxelles, Belgium
Teva Investigational Site 264
Bruxelles, Belgium
Teva Investigational Site 260
Gent, Belgium
Teva Investigational Site 262
Jambes, Belgium
Teva Investigational Site 263
Liège, Belgium
Chile
Teva Investigational Site 160
Rancagua, Chile
Teva Investigational Site 163
Santiago, Chile
Teva Investigational Site 164
Santiago, Chile
Teva Investigational Site 165
Santiago, Chile
Teva Investigational Site 161
Temuco, Chile
Teva Investigational Site 162
Valdivia, Chile
Teva Investigational Site 166
Valparaiso, Chile
Colombia
Teva Investigational Site 185
Bogota, Colombia
Teva Investigational Site 181
Bogotá, Colombia
Teva Investigational Site 182
Cali, Colombia
Teva Investigational Site 180
Floridablanca, Colombia
Czech Republic
Teva Investigational Site 284
Breclav, Czech Republic
Teva Investigational Site 287
Brno, Czech Republic
Teva Investigational Site 286
Liberec, Czech Republic
Teva Investigational Site 280
Olomouc, Czech Republic
Teva Investigational Site 281
Olomouc, Czech Republic
Teva Investigational Site 285
Olomouc, Czech Republic
Teva Investigational Site 283
Tabor, Czech Republic
Denmark
Teva Investigational Site 301
Hvidovre, Denmark
Teva Investigational Site 300
Odense, Denmark
Hungary
Teva Investigational Site 401
Balassagyarmat, Hungary
Teva Investigational Site 400
Miskolc, Hungary
Teva Investigational Site 404
Mosonmagyaróvár, Hungary
Teva Investigational Site 403
Sopron, Hungary
Teva Investigational Site 405
Törökbálint, Hungary
Israel
Teva Investigational Site 423
Ashkelon, Israel
Teva Investigational Site 430
Beer-Sheva, Israel
Teva Investigational Site 431
Haifa, Israel
Teva Investigational Site 432
Haifa, Israel
Teva Investigational Site 425
Jerusalem, Israel
Teva Investigational Site 428
Jerusalem, Israel
Teva Investigational Site 429
Jerusalem, Israel
Teva Investigational Site 426
Kfar Saba, Israel
Teva Investigational Site 422
Petach Tikva, Israel
Teva Investigational Site 427
Ramat Gan, Israel
Teva Investigational Site 433
Ramat Gan, Israel
Teva Investigational Site 421
Rehovot, Israel
Teva Investigational Site 420
Tel-Aviv, Israel
Malaysia
Teva Investigational Site 705
Batu Caves, Malaysia
Teva Investigational Site 700
Kuala Lumpur, Malaysia
Teva Investigational Site 702
Kuala Lumpur, Malaysia
Teva Investigational Site 703
Kuantan, Malaysia
Teva Investigational Site 701
Penang, Malaysia
Teva Investigational Site 704
Taiping, Malaysia
New Zealand
Teva Investigational Site 723
Auckland, New Zealand
Teva Investigational Site 722
Christchurch, New Zealand
Teva Investigational Site 726
Christchurch, New Zealand
Teva Investigational Site 724
Dunedin, New Zealand
Teva Investigational Site 727
Hamilton, New Zealand
Teva Investigational Site 720
Tauranga, New Zealand
Teva Investigational Site 721
Wellington, New Zealand
Philippines
Teva Investigational Site 744
Governor Mangubat Drive, Dasma, Philippines
Teva Investigational Site 742
Manila, Philippines
Teva Investigational Site 740
Quezon City, Philippines
Teva Investigational Site 741
Quezon City, Philippines
Teva Investigational Site 743
Quezon City, Philippines
Teva Investigational Site 745
Quezon City, Philippines
Poland
Teva Investigational Site 507
Bialystok, Poland
Teva Investigational Site 509
Bydgoszcz, Poland
Teva Investigational Site 501
Bystra, Poland
Teva Investigational Site 500
Ostrow Wielkopolski, Poland
Teva Investigational Site 511
Poznan, Poland
Teva Investigational Site 502
Sopot, Poland
Teva Investigational Site 504
Tarnow, Poland
Russian Federation
Teva Investigational Site 545
Barnaul, Russian Federation
Teva Investigational Site 551
Kazan, Russian Federation
Teva Investigational Site 549
Kemerovo, Russian Federation
Teva Investigational Site 550
Nizhniy Novgorod, Russian Federation
Teva Investigational Site 553
Novosibirsk, Russian Federation
Teva Investigational Site 555
Novosibirsk, Russian Federation
Teva Investigational Site 542
St. Petersburg, Russian Federation
Teva Investigational Site 552
Tomsk, Russian Federation
Teva Investigational Site 546
Yaroslavl, Russian Federation
South Africa
Teva Investigational Site 581
Cape Town, South Africa
Teva Investigational Site 584
Cape Town, South Africa
Teva Investigational Site 586
Cape Town, South Africa
Teva Investigational Site 587
Centurion, South Africa
Teva Investigational Site 582
Durban, South Africa
Teva Investigational Site 585
Durban, South Africa
Teva Investigational Site 580
Johannesburg, South Africa
Teva Investigational Site 589
Johannesburg, South Africa
Teva Investigational Site 583
Pretoria, South Africa
Teva Investigational Site 588
Pretoria, South Africa
Sweden
Teva Investigational Site 602
Göteborg, Sweden
Teva Investigational Site 604
Göteborg, Sweden
Teva Investigational Site 603
Linköping, Sweden
Teva Investigational Site 601
Malmö, Sweden
Thailand
Teva Investigational Site 780
Bangkok, Thailand
Teva Investigational Site 782
Bangkok, Thailand
Teva Investigational Site 783
Bangkok, Thailand
Teva Investigational Site 781
Muang, Thailand
Teva Investigational Site 784
Nakhon Ratchasima, Thailand
Sponsors and Collaborators
Teva Branded Pharmaceutical Products, R&D Inc.
Investigators
Study Director: Medical Expert, MD TEVA
  More Information

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Teva Branded Pharmaceutical Products, R&D Inc.
ClinicalTrials.gov Identifier: NCT01287039     History of Changes
Other Study ID Numbers: C38072/3082 
Study First Received: January 28, 2011
Results First Received: March 23, 2016
Last Updated: May 26, 2016
Health Authority: United States: Food and Drug Administration
Australia: Department of Health and Ageing Therapeutic Goods Administration
Belgium: Federal Agency for Medicinal Products and Health Products
Canada: Health Canada
Chile: Ministry of Health
Colombia: National Institutes of Health
Czech Republic: State Institute for Drug Control
Denmark: Danish Medicines Agency
Finland: Finnish Medicines Agency
Hungary: National Institute of Pharmacy
Israel: Israeli Health Ministry Pharmaceutical Administration
Malaysia: Ministry of Health
New Zealand: Ministry of Health
Norway: Norwegian Medicines Agency
Philippines: Bureau of Food and Drugs
Poland: Office for Registration of Medicinal Products, Medical Devices and Biocidal Products
Russia: Pharmacological Committee, Ministry of Health
South Africa: Medicines Control Council
Sweden: Medical Products Agency
Thailand: Food and Drug Administration

Additional relevant MeSH terms:
Asthma
Pulmonary Eosinophilia
Bronchial Diseases
Respiratory Tract Diseases
Lung Diseases, Obstructive
Lung Diseases
Respiratory Hypersensitivity
Hypersensitivity, Immediate
Hypersensitivity
Immune System Diseases
Hypereosinophilic Syndrome
Eosinophilia
Leukocyte Disorders
Hematologic Diseases

ClinicalTrials.gov processed this record on September 27, 2016